Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study.

ABSTRACT:

Background

On September 5, 2019, British Columbia announced a new policy (the Biosimilars Initiative) to switch from originator to biosimilar infliximab for patients with inflammatory bowel diseases.

Objective

To monitor the impacts of the policy on the use of medications and health services during the first year of the policy.

Methods

In this population-based cohort study, we used administrative health data to construct three historical cohorts and one policy cohort of patients with inflammatory bowel diseases who used the originator infliximab. We then monitored the cumulative incidence of medications and health services. Log-likelihood ratios were used to quantify differences between the policy cohort and the average of the historical cohorts.

Results

The co

SUBMITTER: Fisher A 

PROVIDER: S-EPMC9995207 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature